Home
>
National Drug Code (NDC)
>
VIDEX EC
VIDEX EC - 0087-6671-17 - (didanosine)
Drug Information of VIDEX EC
| Product NDC: | 0087-6671 |
| Proprietary Name: | VIDEX EC |
| Non Proprietary Name: | didanosine |
| Active Ingredient(s): | 125 mg/1 & nbsp; didanosine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, DELAYED RELEASE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of VIDEX EC
| Product NDC: | 0087-6671 |
| Labeler Name: | Bristol-Myers Squibb Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021183 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20001031 |
Package Information of VIDEX EC
| Package NDC: | 0087-6671-17 |
| Package Description: | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0087-6671-17) |
NDC Information of VIDEX EC
| NDC Code | 0087-6671-17 |
| Proprietary Name | VIDEX EC |
| Package Description | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0087-6671-17) |
| Product NDC | 0087-6671 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | didanosine |
| Dosage Form Name | CAPSULE, DELAYED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20001031 |
| Marketing Category Name | NDA |
| Labeler Name | Bristol-Myers Squibb Company |
| Substance Name | DIDANOSINE |
| Strength Number | 125 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
